Literature DB >> 25986748

Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway.

Julianne D Jett1, Angela M Boley, Milena Girotti, Amiksha Shah, Daniel J Lodge, David A Morilak.   

Abstract

RATIONALE: Acute low-dose administration of the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, produces rapid and sustained antidepressant-like effects in humans and rodents. Recently, we found that the long-lasting effect of ketamine on the forced swim test requires ventral hippocampal (vHipp) activity at the time of drug administration. The medial prefrontal cortex (mPFC), a target of the vHipp dysregulated in depression, is important for cognitive flexibility and response strategy selection. Deficits in cognitive flexibility, the ability to modify thoughts and behaviors in response to changes in the environment, are associated with depression. We have shown that chronic stress impairs cognitive flexibility on the attentional set-shifting test (AST) and induces a shift from active to passive response strategies on the shock-probe defensive burying test (SPDB).
OBJECTIVE: In this study, we tested the effects of ketamine on chronic stress-induced changes in cognitive flexibility and coping behavior on the AST and SPDB, respectively. Subsequently, we investigated vHipp-mPFC plasticity as a potential mechanism of ketamine's therapeutic action.
RESULTS: Ketamine reversed deficits in cognitive flexibility and restored active coping behavior in chronically stressed rats. Further, high frequency stimulation in the vHipp replicated ketamine's antidepressant-like effects on the forced swim test and AST, but not on the SPDB.
CONCLUSION: These results show that ketamine restores cognitive flexibility and coping response strategy compromised by stress. Activity in the vHipp-mPFC pathway may represent a neural substrate for some of the antidepressant-like behavioral effects of ketamine, including cognitive flexibility, but other circuits may mediate the effects of ketamine on coping response strategy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986748      PMCID: PMC4536154          DOI: 10.1007/s00213-015-3957-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  56 in total

1.  A call to action: overcoming anxiety through active coping.

Authors:  J E LeDoux; J M Gorman
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

Review 2.  Evolution of remission as the new standard in the treatment of depression.

Authors:  A A Nierenberg; E C Wright
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 3.  The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies.

Authors:  C Heim; C B Nemeroff
Journal:  Biol Psychiatry       Date:  2001-06-15       Impact factor: 13.382

Review 4.  Recent developments in understanding the psychosocial aspects of depression.

Authors:  T Harris
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

Review 5.  Cognitive deficits in depression: possible implications for functional neuropathology.

Authors:  M P Austin; P Mitchell; G M Goodwin
Journal:  Br J Psychiatry       Date:  2001-03       Impact factor: 9.319

Review 6.  The genetics of major depressive disorder.

Authors:  G S Malhi; J Moore; P McGuffin
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

7.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

8.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

9.  Changes in synaptic plasticity in the rat hippocampo-medial prefrontal cortex pathway induced by repeated treatments with fluvoxamine.

Authors:  Satoshi Ohashi; Machiko Matsumoto; Hiroshi Otani; Kiyoshi Mori; Hiroko Togashi; Ken-ichi Ueno; Asako Kaku; Mitsuhiro Yoshioka
Journal:  Brain Res       Date:  2002-09-13       Impact factor: 3.252

10.  Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat.

Authors:  Natalia Gass; Adam James Schwarz; Alexander Sartorius; Esther Schenker; Celine Risterucci; Michael Spedding; Lei Zheng; Andreas Meyer-Lindenberg; Wolfgang Weber-Fahr
Journal:  Neuropsychopharmacology       Date:  2013-10-18       Impact factor: 7.853

View more
  27 in total

1.  Chronic treatment with galantamine rescues reversal learning in an attentional set-shifting test after experimental brain trauma.

Authors:  Ihuoma Njoku; Hannah L Radabaugh; Melissa A Nicholas; Lindsay A Kutash; Darik A O'Neil; Ian P Marshall; Jeffrey P Cheng; Anthony E Kline; Corina O Bondi
Journal:  Exp Neurol       Date:  2019-01-31       Impact factor: 5.330

2.  Impact of impaired glucose metabolism on responses to a psychophysical stressor: modulation by ketamine.

Authors:  Brett Melanson; Thomas Lapointe; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

Review 3.  Prefrontal cortex executive processes affected by stress in health and disease.

Authors:  Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-06       Impact factor: 5.067

4.  Therapeutic Effects of Extinction Learning as a Model of Exposure Therapy in Rats.

Authors:  Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Neuropsychopharmacology       Date:  2016-07-15       Impact factor: 7.853

Review 5.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

6.  Ketamine Corrects Stress-Induced Cognitive Dysfunction through JAK2/STAT3 Signaling in the Orbitofrontal Cortex.

Authors:  Michael S Patton; Daniel J Lodge; David A Morilak; Milena Girotti
Journal:  Neuropsychopharmacology       Date:  2016-10-17       Impact factor: 7.853

7.  Deficits in cognitive flexibility induced by chronic unpredictable stress are associated with impaired glutamate neurotransmission in the rat medial prefrontal cortex.

Authors:  Julianne D Jett; Sarah E Bulin; Lauren C Hatherall; Carlie M McCartney; David A Morilak
Journal:  Neuroscience       Date:  2017-01-26       Impact factor: 3.590

8.  Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.

Authors:  Kristian Gaarn du Jardin; Nico Liebenberg; Heidi Kaastrup Müller; Betina Elfving; Connie Sanchez; Gregers Wegener
Journal:  Psychopharmacology (Berl)       Date:  2016-05-28       Impact factor: 4.530

Review 9.  Anteroventral bed nuclei of the stria terminalis neurocircuitry: Towards an integration of HPA axis modulation with coping behaviors - Curt Richter Award Paper 2017.

Authors:  Jason J Radley; Shane B Johnson
Journal:  Psychoneuroendocrinology       Date:  2017-12-24       Impact factor: 4.905

Review 10.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.